Comparison · NCT04504916-841dff44
Zilovertamab Vedotin Q1/3W vs Zilovertamab Vedotin Q2/3W: Number of Participants Who Discontinued Study Treatment Due to an AE
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Zilovertamab Vedotin Q1/3W vs Zilovertamab Vedotin Q2/3W: Number of Participants Who Discontinued Study Treatment Due to an AE. Trial comparisons, record NCT04504916-841dff44. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT04504916-841dff44
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.1 | 0.0493 | 0.192 | wilson | |
| Risk in group 2 | 0.188 | 0.0889 | 0.353 | wilson | |
| Risk difference, group 1 minus group 2 | -0.0875 | -0.261 | 0.0476 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.533 | 0.195 | 1.46 | log | |
| Odds ratio, group 1 over group 2 | 0.481 | 0.148 | 1.57 | log | |
| Number needed to treat, for one fewer participant with the outcome on Zilovertamab Vedotin Q1/3W than on Zilovertamab Vedotin Q2/3W | 11.4 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Zilovertamab Vedotin Q1/3W | Participants received IV zilovertamab vedotin 2.5 mg/kg on Day 1 of each repeated 21-day cycle (Q1/3W). Treatment continued until progressive disease or discontinuation. | 7 | 70 | OG000 |
| Group 2 | Zilovertamab Vedotin Q2/3W | Participants received IV zilovertamab vedotin 1.75 mg/kg on Day 1 and Day 8 of each repeated 21-day cycle (Q2/3W). Treatment continued until progressive disease or discontinuation. | 6 | 32 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Number of Participants Who Discontinued Study Treatment Due to an AE
- Description
An AE was any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening of a preexisting condition that was temporally associated with the use of the Sponsor's product, was also an AE. The number of participants who discontinued study treatment due to an AE was reported.
- Time frame
- Up to ~11 months
- Population
- FAS which included all participants who received ≥1 dose of study drug
Source ClinicalTrials.gov
Trial
- Title
- A Study of Zilovertamab Vedotin (MK-2140/VLS-101) in Participants With Solid Tumors (MK-2140-002)
- NCT number
- NCT04504916
- Phases
- PHASE2
- Conditions
Triple-negative Breast Cancer, Non-squamous Non-small-cell Lung Cancer, NSCLC, Estrogen-receptor-positive Breast Cancer, Progesterone-receptor-positive Breast Cancer, Estrogen-receptor-negative Breast Cancer, ER-negative Breast Cancer, Progesterone-receptor Negative Breast Cancer, PR-negative Breast Cancer, HER2-negative Breast Cancer, ER-positive Breast Cancer, PR-positive Breast Cancer, Platinum-resistant Ovarian Cancer, Gastric Cancer, Pancreatic Cancer
- Interventions
- Zilovertamab vedotin
- Lead sponsor
- VelosBio Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
- Results first posted
- 2024-08-15
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT04504916?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT04504916-841dff44